Autolus Therapeutics Q2 EPS $(0.22) Misses $(0.19) Estimate, Company Exits Quarter With Cash & Equivalents Worth $705.9M
Portfolio Pulse from Benzinga Newsdesk
Autolus Therapeutics (NASDAQ:AUTL) reported a Q2 EPS of $(0.22), missing the analyst estimate of $(0.19) by 15.79%. The company ended the quarter with $705.9M in cash and equivalents.
August 08, 2024 | 11:07 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Autolus Therapeutics reported a Q2 EPS of $(0.22), missing the analyst estimate of $(0.19) by 15.79%. The company ended the quarter with $705.9M in cash and equivalents.
The EPS miss is likely to negatively impact the stock price in the short term as it indicates the company is not meeting analyst expectations. However, the substantial cash reserves may provide some cushion.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100